PellePharm Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PellePharm Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11021
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥100,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PellePharm Inc (PellePharm), a subsidiary of BridgeBio Inc, is a biotechnology company that develops and commercializes treatments for rare genetic dermatological conditions. The company’s lead clinical program, Patidegib, is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor that treats basal cell carcinomas (BCCs), Gorlin Syndrome and other indications. Patidegib is designed to work by blocking the hedgehog signaling pathway. It enhances chemically a naturally occurring hedgehog pathway inhibitor by preventing the smoothened signal, leading to normal cell function and stopping the excessive production of tumors in patients with Gorlin Syndrome and BCCs. PellePharm is headquartered in San Francisco, California, the US.

PellePharm Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PellePharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PellePharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PellePharm Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
PellePharm Raises USD7.5 Million in Venture Financing 10
PellePharm Secures Additional USD20 Million in Series B Financing 11
PellePharm Raises USD3.2 Million in Financing 12
PellePharm Raises USD0.7 Million in Financing 13
PellePharm Raises USD4.6 Million in Venture Financing 14
PellePharm Raises USD1.8 Million in Venture Financing 15
PellePharm Raises USD0.1 Million in Venture Financing 16
PellePharm Raises USD1.3 Million in Venture Financing 17
PellePharm Raises USD0.5 Million in Venture Financing 18
Licensing Agreements 19
PellePharm Enters into Licensing Agreement with Infinity Pharma 19
Equity Offering 20
PellePharm Secures Investment from BridgeBio Pharma 20
PellePharm Inc – Key Competitors 21
PellePharm Inc – Key Employees 22
PellePharm Inc – Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Corporate Communications 24
Jan 04, 2018: BridgeBio Pharma Appoints Sanuj Ravindran, M.D., and Eric Michael David, M.D. as CEOs-in-Residence to Lead Dermatology and Gene Therapy Programs 24
Jan 04, 2018: PellePharm Appoints Sanuj K. Ravindran, M.D., as President and Chief Executive Officer 25
Clinical Trials 26
Nov 20, 2017: FDA Grants Breakthrough Therapy Designation and Orphan Drug Designation to Pellepharm for Topical Patidegib in Gorlin Syndrome 26
Jul 31, 2017: PellePharm Announces Topline Results from Phase 2 Study of Topical Patidegib in Gorlin Syndrome Basal Cell Carcinomas 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
PellePharm Inc, Pharmaceuticals & Healthcare, Key Facts 2
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PellePharm Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PellePharm Inc, Deals By Therapy Area, 2012 to YTD 2018 8
PellePharm Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
PellePharm Raises USD7.5 Million in Venture Financing 10
PellePharm Secures Additional USD20 Million in Series B Financing 11
PellePharm Raises USD3.2 Million in Financing 12
PellePharm Raises USD0.7 Million in Financing 13
PellePharm Raises USD4.6 Million in Venture Financing 14
PellePharm Raises USD1.8 Million in Venture Financing 15
PellePharm Raises USD0.1 Million in Venture Financing 16
PellePharm Raises USD1.3 Million in Venture Financing 17
PellePharm Raises USD0.5 Million in Venture Financing 18
PellePharm Enters into Licensing Agreement with Infinity Pharma 19
PellePharm Secures Investment from BridgeBio Pharma 20
PellePharm Inc, Key Competitors 21
PellePharm Inc, Key Employees 22

List of Figures
PellePharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PellePharm Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PellePharm Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[PellePharm Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TenneT Holding BV:企業の戦略的SWOT分析
    TenneT Holding BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • MTY Food Group Inc.:戦略・SWOT・企業財務分析
    MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report Summary MTY Food Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Dyson Group Plc:企業の戦略的SWOT分析
    Dyson Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Rothschild Bank Ag
    Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report Summary Rothschild Bank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Robinson Helicopter Company, Inc.:企業の戦略・SWOT・財務分析
    Robinson Helicopter Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Robinson Helicopter Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Vygon SA:企業の戦略的SWOT分析
    Vygon SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Professional Insurance Corp Zambia PLC:企業の戦略・SWOT・財務分析
    Professional Insurance Corp Zambia PLC - Strategy, SWOT and Corporate Finance Report Summary Professional Insurance Corp Zambia PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Opiant Pharmaceuticals Inc (OPNT):医療機器:M&Aディール及び事業提携情報
    Summary Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction and eating disorders. It focuses on developing treatments to reverse opioid overdoses, for overweight and obes …
  • NEC Capital Solutions Ltd. (8793):企業の財務・戦略的SWOT分析
    NEC Capital Solutions Ltd. (8793) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Barratt Developments Plc:企業の戦略・SWOT・財務情報
    Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report Summary Barratt Developments Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Neogen Corp (NEOG):企業の財務・戦略的SWOT分析
    Neogen Corp (NEOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Shoal Point Energy Ltd (SHP):石油・ガス:M&Aディール及び事業提携情報
    Summary Shoal Point Energy Ltd (Shoal Point Energy) is an oil and gas exploration and development company that acquires, develops, explores, and produces petroleum products. The company holds interests in Green Point Oil-in-Shale and Humber Arm Shale project. It also holds interests in the explorati …
  • IDT Corporation:企業の戦略・SWOT・財務情報
    IDT Corporation - Strategy, SWOT and Corporate Finance Report Summary IDT Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Stryker Corporation:企業の戦略・SWOT・財務情報
    Stryker Corporation - Strategy, SWOT and Corporate Finance Report Summary Stryker Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ems-Chemie Holding AG (EMSN):企業の財務・戦略的SWOT分析
    Summary Ems-Chemie Holding AG (Ems-Chemie) is a chemical company that manufactures and markets high performance polymers and specialty chemicals. The company's products include bonding products, polyamides, damping systems, sealants, coating products, thermoplastic material, technical fibers, and te …
  • Guangdong Biolight Meditech Co Ltd (300246):医療機器:M&Aディール及び事業提携情報
    Summary Guangdong Biolight Meditech Co Ltd (Biolight) is a medical device company. The company operates in the business of research, development, production and sale of medical treatment monitors, medical consumables and healthcare solutions. It offers patient monitors, hemodialysis products and hom …
  • Kazakhtelecom (KZTK):企業の財務・戦略的SWOT分析
    Kazakhtelecom (KZTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SMART Technologies Inc.:企業の戦略的SWOT分析
    SMART Technologies Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Fomento de Construcciones y Contratas SA (FCC):企業の財務・戦略的SWOT分析
    Fomento de Construcciones y Contratas SA (FCC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆